Hong Kong Healthcare Stocks Split: Far Eastern Pharma's FDA Gamble vs. Real Estate Quagmire

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Far Eastern Pharma (0512.HK) is betting big on its GPN00833 nano-suspension eye drops. The specialty drugmaker completed first patient dosing in Phase III trials for post-cataract inflammation last week, with FDA submission already filed—a rare bright spot in Hong Kong's biotech sector.

Poly Platinum Medical (1515.HK) took a different approach, overhauling its hospital acquisition strategy in early October. The move sparked a 5% intraday surge as investors weighed scalability against profitability in China's fragmented healthcare market.

MicroPort Scientific (0853.HK) granted 17.8 million stock options to management, signaling confidence in its cardiovascular device pipeline despite near-term market headwinds. The move drew mixed reactions from analysts tracking its U.S. market entry prospects.

Haoya Medical (6078.HK) faced harsher realities when Morgan Stanley slashed its target price by 20% in late September, triggering a 5% single-day plunge. The tumor hospital operator's premium valuation now faces intense scrutiny amid pricing pressures.

The sector's identity crisis became stark with New Ming China (2699.HK)—a property developer—remaining suspended over delayed financial reporting. Meanwhile, Convergence Tech (1729.HK) reported 75% interim profit growth from server sales, underscoring how loosely defined "healthcare" tags can mislead investors.

Source: Global Report The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.